Cartalax (Cartalax) bioregulator 20 mg

Kartalax is a short bioregulatory peptide with widespread systemic action due to its effect on fibroblasts. You can buy it in our online store. It has been proven that it benefits the skin and other connective tissues, as well as the kidneys. Research shows that Kartalax increases the rate of cell proliferation and beneficially alters the levels of various cytokines and signaling molecules associated with aging.
In general, it improves cell health and proliferation while reducing cell death. Kartalax is considered an anti-aging peptide that restores old cells to a younger state and prolongs the overall condition of tissues.

Kartalax is a short peptide with bioregulatory properties. First of all, it affects fibroblasts, which are ubiquitous cells found in everything: from cartilage to skin, blood vessels, and kidneys. Studies show that Kartalax affects cell proliferation and apoptosis through
several molecular mechanisms, including increasing levels of Ki-67,
lowering p53 signaling, and activating NF-kB signaling.
Cartalax is classified as an antiaging bioregulator because it reduces aging, restores the functions of old cells, and appears to slow overall tissue aging.

Cartalax and leather

Skin studies show that Kartalax increases proliferation, tissue regeneration, and extracellular matrix remodeling, especially in older animals, while simultaneously reducing apoptosis.
This effect appears to be mediated by fibroblasts, cells that are primarily responsible for the deposition of extracellular matrix in tendons, skin, and cartilage.

It seems that Kartalax and other similar peptides inhibit the synthesis of
MMP-9, which is known to increase during skin aging, simultaneously increasing the expression of Ki-67 and CD98hc, which are less
• intensively expressed during cell aging. Kartalax also suppresses apoptosis by means of the caspase pathway.

In recent years, Vladimir Khavinson has shown that Kartalax and a number of other short peptides are multifunctional. In other words, these peptides are less tissue-specific than some other bioregulatory peptides, since the processes they affect are ubiquitous in the body. In particular, it was shown that Kartalax stimulates the proliferation of skin cells, slows down apoptosis, improves microcirculation and increases the functional activity of skin fibroblasts, which leads to an improvement in the content of carnosine, collagen, cytokines and growth factors
. Havinson notes that these various functions make multifunctional peptides, such as Kartalax 20 mg, important antioxidants and immunoprotectors.

Cartalax and cartilage

It is worth noting that fibroblasts are one of the most universal cells of the human body. They are responsible for the production of components of the extracellular matrix in a number of tissues, from skin to bones and cartilage. Much has been said about the ability of Kartalax to improve cartilage function and joint health, but are there any studies that support this statement

The direct answer is no. There are no studies devoted to cartilage and Kartalax, which would give the peptide such a name. However, there are numerous studies of fibroblasts and Kartalax, which suggest that the peptide will be of great benefit to cartilage. In the end, studies show that fibroblasts are the main regulators of cartilage homeostasis. Kartalax affects the following components of fibroblasts.

• AP-1
• NF-KB
• CCN1
• THF-B
• TNF-α
• MMP-1
• MMP-3
• MMP-8
• MMP-9

Now it is best to think of the role of Kartalax as a balancing agent.
In other words, Kartalax does not affect only one of the components of fibroblasts listed above, but helps to normalize and balance the function of fibroblasts so that they work as efficiently as possible. This effect is especially pronounced in old cells, which experience greater dysregulation than young cells.

Take, for example, MMP-1, which is important for tissue remodeling, embryonic development, and painful processes such as arthritis and metastasis. Its main task is to break down interstitial collagen types I, II and III. This breakdown is necessary for tissues to change and adapt to new stresses, but it can become pathological if it is excessive or not balanced by collagen deposition. Other MMPs have similar functions, all of which are balanced by Kartalax, providing a balance between the breakdown and growth of tissues.

Given its widespread effect on fibroblast function, it is not surprising that Kartalax is being studied for a number of connective tissue diseases, including arthritis, osteoporosis, degenerative disc disease, gout, and some systemic connective tissue diseases such as lupus.

Kartalax and kidney health

In early studies, it was found that polypeptide isolates from calf kidneys can stimulate cell renewal in the kidneys of old rats.
This study showed that polypeptide isolates work by increasing the levels of the proliferation marker Ki-67 and decreasing the levels of the pro-apoptotic peptide p53. The analysis of the isolate showed that two peptides, Cartalax (AED) and T-35 (EDL), were present in the polypeptide isolate, although they did not make up all of it. This prompted scientists to further study the properties and functions of petids such as Kartalax.

Studies on kidney cell cultures show that Kartalax increases cell proliferation while simultaneously reducing markers of aging, such as proteins p16, p21 and p53. In addition, Kartalax in a dose of 20 mg increases the expression of SIRT-6, the levels of which are closely correlated with aging. Low levels of SIRT-6 are thought to actually cause aging.

Kartalax and age

The above topics bypass the obvious fact that Kartalax is a geroprotective bioregulatory peptide. Like many other short bioregulators, Kartalax appears to have the most profound effect on old cells, returning them to a more youthful state.
Studies of Kartalax and many other bioregulators show that they affect the expression of a number of gene products that are known to play an important role in the aging process. Kartalax and other bioregulators have different effects on genes such as IGF1, FOXO1, TERT, TNKS2 and NF-kB.
Changes in expression levels are also significant: from 1.6 to 5.6 times 17.

Kartalax Short description

Kartalax is a short bioregulatory peptide with a widespread systemic effect due to its effect on fibroblasts. It has been proven that it benefits the skin and other connective tissues, as well as the kidneys. Studies show that Kartalax increases the rate of cell proliferation and beneficially changes the levels of various cytokines and signaling molecules associated with aging. Overall, it improves cell health and proliferation while reducing cell death. Kartalax is considered an anti-aging peptide that restores old cells to a younger state and prolongs the overall condition of tissues.